Wait, What? NAD+ Is Both a Recyclable Electron Carrier and a Consumable Signalling Molecule
Nicotinamide adenine dinucleotide is usually introduced as NAD+ and NADH in respiration. That is correct, but incomplete. NAD+ also serves as a chemical substrate for sirtuins, PARPs, CD38, SARM1 and other enzymes that break the molecule and use part of it to control proteins or signalling.
This creates two very different jobs:
- redox cycling: NAD+ accepts electrons to become NADH and can be regenerated;
- consumptive signalling: enzymes cleave NAD+ and the cell must rebuild it.
NAD homeostasis is therefore a balance among synthesis, redox cycling, compartment transport and irreversible consumption.
The One-Sentence Answer
Learn NAD+ metabolism by tracing where NAD+ is made, where NADH is generated and reoxidised, which enzymes consume NAD+ rather than recycle it, and how separate nuclear, cytosolic and mitochondrial pools communicate without becoming one perfectly mixed reservoir.
Stage 1: NAD+ and NADH Form a Redox Pair
NAD+ accepts a hydride equivalent during many metabolic reactions and becomes NADH. NADH can later donate those reducing equivalents. The ratio between oxidised and reduced forms helps constrain which metabolic reactions are favourable.
Stage 2: The Ratio Matters More Than a Single Number
A cell may contain substantial NAD but still experience redox limitation if too much of the pool is trapped as NADH. Conversely, low NADH can reflect either strong oxidation or poor substrate flow. Pool size and redox state answer different questions.
Stage 3: Glycolysis Requires NAD+ Regeneration
Glyceraldehyde-3-phosphate dehydrogenase reduces NAD+ during glycolysis. If cytosolic NAD+ is not regenerated, glycolytic flux eventually stops even when glucose remains available.
Stage 4: Lactate Dehydrogenase Can Regenerate Cytosolic NAD+
Converting pyruvate to lactate oxidises NADH back to NAD+. The pathway therefore preserves glycolytic redox balance, not merely “makes lactate”.
Stage 5: Mitochondria Reoxidise NADH Through Respiration
Matrix NADH donates electrons to respiratory complex I. Oxidative phosphorylation then links electron transfer to proton pumping and ATP production.
Connect this with Mitochondria and Mitochondrial Dynamics.
Stage 6: Cytosolic NADH Does Not Simply Diffuse Through the Inner Mitochondrial Membrane
The reducing equivalents of cytosolic NADH can be transferred through shuttle systems. The malate–aspartate shuttle can regenerate mitochondrial NADH, while the glycerol-3-phosphate shuttle transfers electrons through a flavin-linked route.
Stage 7: Cells Must Also Synthesize NAD+
Because signalling enzymes consume NAD+, redox recycling alone cannot maintain the pool. Cells continually rebuild NAD+ from vitamin-derived and metabolic precursors.
Stage 8: The Salvage Pathway Recycles Nicotinamide
NAMPT converts nicotinamide to nicotinamide mononucleotide, or NMN. NMNAT enzymes then convert NMN to NAD+. In many mammalian tissues, this salvage route is a major source of ongoing NAD+ synthesis.
Stage 9: NMNAT Enzymes Help Create Compartment-Specific NAD Biology
NMNAT1 is strongly associated with the nucleus, NMNAT2 with cytosolic and Golgi-related compartments, and NMNAT3 with mitochondria in some contexts. The exact contribution of each isoform varies by tissue and species.
Stage 10: Nicotinic Acid Uses the Preiss–Handler Pathway
Nicotinic acid can enter NAD+ synthesis through NAPRT and downstream reactions. This is chemically distinct from nicotinamide salvage even though both routes converge on NAD+ production.
Stage 11: Tryptophan Can Feed De Novo NAD+ Synthesis
The kynurenine pathway can convert tryptophan-derived intermediates toward quinolinic acid and ultimately NAD+. Tissue capacity differs substantially, so the presence of the pathway in a diagram does not mean every cell relies on it equally.
Stage 12: Nicotinamide Riboside Adds Another Entry Route
Nicotinamide riboside can be phosphorylated by NRK enzymes to NMN and then converted to NAD+. Precursor use depends on transporter access, enzyme expression and tissue context.
Stage 13: NAD+ Pools Are Compartmentalised
Nuclear and cytosolic NAD+ exchange relatively readily, while the mitochondrial inner membrane creates a stronger boundary. This means one whole-cell NAD measurement can conceal a depleted nuclear pool or a preserved mitochondrial pool.
Stage 14: SLC25A51 Solved a Major Mitochondrial Transport Question
Work published in 2020 identified SLC25A51 as a mammalian mitochondrial NAD+ transporter. Mitochondria therefore do not rely only on internal NAD synthesis; they can import NAD+ through a dedicated inner-membrane carrier.
Stage 15: Compartment Transport Changes Metabolic Capacity
Reducing SLC25A51 can lower mitochondrial NAD availability and constrain TCA-cycle and respiratory functions while leaving other cellular pools less affected. Location changes function.
Stage 16: Sirtuins Consume NAD+ to Modify Proteins
Sirtuins use NAD+ during deacylation reactions and generate nicotinamide as a product. They connect cellular metabolic state with protein modification, chromatin regulation and mitochondrial function.
Stage 17: Different Sirtuins Occupy Different Compartments
SIRT1 is strongly associated with nuclear and cytosolic regulation, while SIRT3, SIRT4 and SIRT5 act largely in mitochondria. The same cofactor therefore supports different signalling networks in different compartments.
Stage 18: PARPs Consume NAD+ During ADP-Ribosylation
PARP1 and related enzymes transfer ADP-ribose units onto proteins during DNA-damage responses and other signalling events. Strong PARP activation can consume substantial NAD+.
Stage 19: DNA Damage Can Become a Metabolic Event
Severe DNA damage can increase PARP-dependent NAD+ consumption. Falling NAD+ can then change ATP production, sirtuin activity and stress responses. Genome damage therefore propagates into metabolism through a shared chemical currency.
Stage 20: CD38 Is a Major NADase in Many Tissues
CD38 cleaves NAD+ and related nucleotides to produce signalling metabolites involved in calcium regulation. Its expression can change with immune activation and ageing, altering NAD turnover.
Stage 21: SARM1 Converts NAD Loss Into an Axon-Degeneration Programme
SARM1 contains NADase activity that can become activated after axonal injury. Rapid NAD destruction helps trigger the energetic and ionic collapse associated with Wallerian degeneration.
Stage 22: NMNAT2 Helps Keep SARM1 Quiet in Healthy Axons
NMNAT2 is a short-lived axonal survival factor. Loss of NMNAT2 after injury changes the balance of NAD-related metabolites and permits SARM1 activation. NAD metabolism therefore participates in a molecular injury sensor.
Stage 23: NAD+ and NADP+ Are Related but Not Interchangeable
NAD kinases phosphorylate NAD+ to NADP+. NADPH is then used heavily for biosynthesis and antioxidant systems. Cells maintain distinct NAD(H) and NADP(H) redox networks.
Stage 24: NADPH Supports Redox Defence
NADPH helps regenerate reduced glutathione and thioredoxin systems. The redox consequences of NAD metabolism therefore extend beyond NADH and respiration.
Connect this with Redox Biology and Oxidative Stress.
Stage 25: NAD+ Links Metabolism to Chromatin
Sirtuin activity and PARP activity both depend on NAD+, creating a route by which nutrient state and DNA damage can influence chromatin. The relationship is not a simple competition formula because enzymes differ in localisation, kinetics and regulation.
Stage 26: NAD Turnover Can Change With Age
Many ageing models show altered NAD synthesis or increased NAD consumption, often involving inflammatory CD38 expression, DNA damage or metabolic stress. The direction and magnitude vary by tissue, species and physiological state.
Stage 27: “NAD Declines With Age” Is a Starting Point, Not a Complete Mechanism
A whole-tissue decline does not identify which cell type changed, which compartment lost NAD+, or whether synthesis fell versus consumption increased. Mechanistic work must separate those possibilities.
Stage 28: NAD-Boosting Precursors Are Biochemically Plausible but Not Universal Solutions
NR, NMN and related precursors can raise NAD-related metabolites in many experimental settings. Human trials have shown that increasing circulating or tissue NAD metabolites is feasible, but clinical benefits vary by endpoint and population. Higher NAD+ is not automatically better in every context.
Stage 29: Cancer Can Depend on NAD Salvage
Some rapidly proliferating cells rely strongly on NAMPT-mediated salvage. This creates therapeutic interest in NAD synthesis, but dependence varies among tumours and normal tissues.
Stage 30: Current 2024–2026 Research Emphasises Regulation, Not Simple Supplementation
A 2024 Nature Reviews Molecular Cell Biology review highlighted the difficulty of targeting NAD metabolism because precursor availability, compartmentation and competing NAD-consuming enzymes all matter. A 2025 review of mitochondrial NAD biology similarly emphasised tissue-specific synthesis, transport and consumption rather than a single universal “NAD level”.
Stage 31: Mass Spectrometry Measures Molecules but Demands Fast Handling
NAD+, NADH, NMN, nicotinamide and related metabolites can change during sample collection and extraction. Quantitative metabolomics therefore requires careful quenching, internal standards and method validation.
Stage 32: Autofluorescence Mainly Sees NADH-Like Reduced Cofactors
NADH contributes intrinsic fluorescence, allowing microscopy without added dyes. Fluorescence lifetime imaging can distinguish free-like and protein-bound states, but NADPH has overlapping fluorescence and interpretation requires care.
Stage 33: Genetically Encoded Sensors Add Compartment Resolution
Peredox, SoNar and newer NAD-related biosensors can report redox ratios or NAD abundance in selected cellular compartments. Sensor calibration, pH sensitivity and expression level can affect results.
Stage 34: Isotope Tracing Measures Turnover
Labelled nicotinamide, nicotinic acid or tryptophan can reveal which synthesis pathway supplies NAD+ and how fast the pool turns over. Turnover can change even when steady-state abundance appears unchanged.
Stage 35: Professional NAD Biology Is a Compartment-and-Flux Problem
The mature question becomes:
Which NAD pool changed, was it altered by synthesis, transport, redox cycling or irreversible consumption, and which downstream enzyme actually experienced that change?
Misconceptions Worth Hunting
- NAD+ is only a respiration coenzyme.
- NADH and NAD+ are different unrelated molecules.
- All cellular NAD+ is one well-mixed pool.
- Mitochondria cannot import NAD+.
- NAD+ used by sirtuins is simply recycled as NADH.
- Higher total NAD+ guarantees higher sirtuin activity.
- All NAD decline with ageing has one cause.
- NAD-boosting supplements are proven universal anti-ageing therapies.
Transfer Check
Block lactate production in a cell with limited mitochondrial redox-shuttle capacity. Could glycolysis slow because cytosolic NAD+ regeneration becomes difficult? Yes.
Reduce SLC25A51. Must nuclear NAD+ fall by the same amount as mitochondrial NAD+? No.
Activate PARP strongly after DNA damage. Could NAD+ fall without any change in NAMPT gene expression? Yes, because consumption increased.
How We Know the Learning Has Held
- Distinguish NAD redox cycling from NAD consumption.
- Explain salvage, Preiss–Handler and de novo synthesis.
- Explain cytosolic versus mitochondrial redox transfer.
- Explain SLC25A51-mediated mitochondrial NAD import.
- Compare sirtuins, PARPs, CD38 and SARM1 as NAD consumers.
- Connect NAD+ with DNA damage, axon degeneration and metabolism.
- Distinguish NAD(H) from NADP(H).
- Choose between metabolomics, autofluorescence, biosensors and isotope tracing.
Model Limits
NAD metabolite extraction is technically difficult. Sensor readouts can be compartment- and pH-sensitive. Tissue-average measurements hide cell-type differences. Human precursor studies establish biochemical effects more consistently than broad health outcomes.
A strong model keeps chemical form + compartment + synthesis route + consumption route + flux visible together.
Research Foundations
- 2024 Nature Reviews Molecular Cell Biology review on regulation and targeting challenges in NAD+ metabolism.
- 2025 review literature on mitochondrial NAD+ synthesis, transport and ageing.
- SLC25A51 discovery and follow-up work on mitochondrial NAD import.
- SARM1–NMNAT2 axon-degeneration biology and modern compartment-targeted NAD sensors.
The Quiet Ending
The beginner asks, “How much NAD+ does the cell have?”
The developing biologist asks, “Which pathway made or consumed it?”
And the professional asks:
Which compartment-specific NAD flux changed, and which metabolic or signalling reaction was therefore enabled, constrained or terminated?
